Profile data is unavailable for this security.
About the company
HOB Biotech Group Corp Ltd is a China-based company primarily engaged in the research and development, production and sales of in vitro diagnostic reagents. The Company provides two categories of products: allergy testing products and self-immune testing products. Its detection techniques include qualitative detection techniques such as enzyme-linked immunosorbent assay, and quantitative detection techniques such as enzyme-linked immunoassay capture method and nano-magnetic particle chemiluminescence method. The brands of allergy testing products include Oboke, Fubok, Shibok and Shibok Plus. The self-immune testing product brands include Norbok and Nabok. It is also engaged in the provision of reagent supporting testing instruments and others. The Company conducts its businesses in the domestic market.
- Revenue in CNY (TTM)401.29m
- Net income in CNY35.26m
- Incorporated2009
- Employees550.00
- LocationHOB Biotech Group Corp LtdNo. 9 Dongyanli RoadSuzhou Industrial ParkSUZHOU 215009ChinaCHN
- Phone+86 51 269561996
- Fax+86 51 262956652
- Websitehttp://www.hob-biotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovita Biological Technology Co Ltd | 720.40m | 332.01m | 5.82bn | 404.00 | 17.46 | 2.85 | -- | 8.07 | 2.44 | 2.44 | 5.30 | 14.98 | 0.3584 | 3.18 | 9.16 | 1,783,177.00 | 16.52 | -- | 17.42 | -- | 80.70 | -- | 46.09 | -- | 16.01 | -- | 0.001 | -- | 7.03 | -- | 15.44 | -- | -- | -- |
| Zhende Medical Co Ltd | 4.04bn | 205.34m | 6.17bn | 6.72k | 30.14 | 1.11 | -- | 1.53 | 0.7684 | 0.7684 | 15.19 | 20.95 | 0.5191 | 3.12 | 6.43 | 601,941.30 | 2.85 | 17.13 | 3.61 | 23.54 | 34.16 | 38.05 | 5.49 | 17.33 | 1.80 | 38.53 | 0.1465 | 29.85 | -32.76 | 23.63 | -70.87 | 8.79 | 21.46 | 47.58 |
| Zhejiang Orient Gene Biotech Co Ltd | 825.60m | -587.36m | 6.49bn | 2.23k | -- | 0.9432 | -- | 7.86 | -2.93 | -2.93 | 4.14 | 34.13 | 0.0949 | 1.17 | 3.19 | 370,058.00 | -7.18 | 29.62 | -8.27 | 38.29 | 39.26 | 59.69 | -75.73 | 35.82 | 3.71 | -- | 0.0744 | 19.24 | -90.65 | 23.46 | -119.23 | -- | 121.04 | -- |
| Shanghai Aohua Phtlctrcty Endscp Co Ltd | 750.04m | 49.97m | 6.92bn | 1.09k | 127.80 | 5.00 | -- | 9.23 | 0.4023 | 0.4023 | 5.56 | 10.27 | 0.4682 | 1.01 | 3.34 | 686,850.10 | 3.26 | 4.37 | 3.66 | 4.80 | 68.88 | 69.25 | 6.97 | 10.91 | 3.33 | -- | 0.0815 | 31.51 | 52.29 | 34.25 | 166.42 | -- | 20.42 | -- |
| Shenzhen Lifotronic Technology Co Ltd | 1.19bn | 381.08m | 7.06bn | 1.48k | 18.51 | 3.62 | -- | 5.92 | 0.8909 | 0.8909 | 2.79 | 4.55 | 0.4834 | 2.27 | 7.49 | 805,792.80 | 15.37 | 13.82 | 21.09 | 16.33 | 67.06 | 61.01 | 31.79 | 26.10 | 2.25 | -- | 0.2434 | 41.51 | 16.55 | 28.78 | 30.66 | 32.27 | -7.91 | -- |
| HOB Biotech Group Corp Ltd | 401.29m | 35.26m | 7.76bn | 550.00 | 219.11 | 9.50 | -- | 19.33 | 0.5614 | 0.5614 | 6.35 | 12.95 | 0.4102 | 1.37 | 8.23 | 729,609.80 | 3.60 | 9.94 | 4.33 | 12.10 | 61.87 | 65.30 | 8.79 | 19.53 | 0.9438 | 39.42 | 0.1192 | 32.59 | 23.10 | 14.38 | 13.64 | 3.34 | 46.19 | -- |
| Shanghai Microport EP MedTech Co Ltd | 383.99m | 35.90m | 9.59bn | 577.00 | 267.04 | 5.54 | -- | 24.96 | 0.0763 | 0.0763 | 0.816 | 3.68 | 0.2081 | 1.30 | 7.04 | 665,493.30 | 1.95 | -- | 2.05 | -- | 57.86 | -- | 9.35 | -- | 13.82 | -- | 0.0109 | -- | 26.46 | -- | 85.17 | -- | -- | -- |
Data as of Nov 15 2024. Currency figures normalised to HOB Biotech Group Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
2.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CPIC Fund Management Co. Ltd.as of 30 Jun 2024 | 114.73k | 0.89% |
| Yimin Asset Management Co., Ltd.as of 30 Jun 2024 | 68.33k | 0.53% |
| Manulife TEDA Fund Management Co., Ltd.as of 30 Jun 2024 | 25.15k | 0.20% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024 | 23.50k | 0.18% |
| Truvalue Asset Management Co. Ltd.as of 30 Jun 2024 | 17.00k | 0.13% |
| Dongxing Asset Management Co. Ltd.as of 30 Jun 2024 | 10.06k | 0.08% |
| Fortune & Royal Asset Management Co., Ltd.as of 30 Jun 2024 | 9.10k | 0.07% |
| CR Yuanta Fund Management Co.,Ltdas of 30 Jun 2024 | 6.80k | 0.05% |
| Bohai Huijin Securities Asset Management Co. Ltd.as of 30 Jun 2024 | 5.90k | 0.05% |
| Western Leadbank Fund Management Co., Ltdas of 30 Jun 2024 | 4.20k | 0.03% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
